| All 2012 Releases |
|---|
 |
Osiris Therapeutics to Present at the 24th Annual Piper Jaffray Healthcare Conference
11-20-12
14.2 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company
focused on developing and marketing products to treat medical conditions
in inflammatory, cardiovascular, orthopedic and wound healing markets,
announced today that C. Randal Mills, Ph.D., President a...
|
|
Osiris Therapeutics Reports Third Quarter 2012 Financial Results
11-05-12
30.0 KB
|
| |
Biosurgery sales up 6-fold over previous year - Osiris regains
worldwide rights to Prochymal
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company
focused on developing and marketing products to treat medical conditions
in ...
|
|
Osiris Therapeutics Announces Third Quarter 2012 Financial Results Conference Call
10-29-12
15.0 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will
report its financial results for the third quarter ended September 30,
2012, on Monday, November 5, 2012. C. Randal Mills, Ph.D., President and
Chief Executive Officer, and Philip R. Jacoby, Jr., Chief ...
|
|
Osiris Therapeutics Names Lode Debrabandere Chief Operating Officer
10-22-12
14.6 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR) announced today it has promoted
Lode Debrabandere, Ph.D. to the role of Chief Operating Officer (COO)
reporting directly to Chief Executive Officer, C. Randal Mills, Ph.D.
Dr. Debrabandere has been with Osiris since 2006 in various...
|
|
Swissmedic Invokes Rapid Authorization Procedures for Prochymal Review
09-28-12
16.0 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR) announced today that it has been
notified by Swissmedic, the Swiss agency responsible for the evaluation
of drugs, that Prochymal® (remestemcel-L) will be evaluated under
its Rapid Authorization Procedures. This designation, a...
|
|
Osiris Therapeutics Regains Worldwide Rights to Prochymal and Chondrogen
09-28-12
14.0 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR) today announced the conclusion of
its collaboration with Genzyme, a Sanofi company. As the Collaboration
Agreement is now ended, all rights to Prochymal® and ChondrogenTM
worldwide revert back to Osiris. Osiris is now free to ...
|
|
Osiris Therapeutics Announces Change in its Board of Directors
09-20-12
14.9 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR) announced today the passing of one
of its Board Members, Gregory H. Barnhill. Mr. Barnhill has served on
Osiris' Board of Directors since the company went public in August of
2006 and was a member of the Audit, Nominating and Compe...
|
|
Osiris Therapeutics to Present at 2012 UBS Global Life Sciences Conference
09-19-12
14.2 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company
focused on developing and marketing products to treat medical conditions
in inflammatory, cardiovascular, orthopedic and wound healing markets,
announced today that C. Randal Mills, Ph.D., President a...
|
|
Osiris Therapeutics Reports Second Quarter 2012 Financial Results
07-30-12
30.4 KB
|
| |
Biosurgery sales rise 43% over prior quarter, Prochymal® becomes
first approved stem cell drug and company ends the first half with $40
million in cash and no debt
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company
...
|
|
Osiris Therapeutics Announces Second Quarter 2012 Financial Results Conference Call
07-23-12
15.2 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will
report its financial results for the second quarter ended June 30, 2012,
on Monday, July 30, 2012. C. Randal Mills, Ph.D., President and Chief
Executive Officer, and Philip R. Jacoby, Jr., Chief Financi...
|
|
Board of Directors
Press Releases